chlorzoxazone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
626 95-25-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • chlorzoxazone
  • 5-Chlorobenzoxazolidone
  • chlorzoxazon
  • chloroxazone
A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
  • Molecular weight: 169.56
  • Formula: C7H4ClNO2
  • CLOGP: 1.87
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 38.33
  • ALOGS: -1.76
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.50 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.25 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 196.38 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Aug. 15, 1958 FDA JANSSEN R AND D

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 135.47 65.97 28 53 21006 2336998

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Secondary adrenocortical insufficiency 97.44 85.44 11 27 173 1746570

Pharmacologic Action:

SourceCodeDescription
ATC M03BB03 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Oxazol, thiazine, and triazine derivatives
ATC M03BB53 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Oxazol, thiazine, and triazine derivatives
ATC M03BB73 MUSCULO-SKELETAL SYSTEM
MUSCLE RELAXANTS
MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
Oxazol, thiazine, and triazine derivatives
FDA PE N0000175730 Centrally-mediated Muscle Relaxation
CHEBI has role CHEBI:51371 muscle relaxant
CHEBI has role CHEBI:35717 sedative
MeSH PA D002491 Central Nervous System Agents
MeSH PA D009125 Muscle Relaxants, Central
MeSH PA D009465 Neuromuscular Agents
MeSH PA D018373 Peripheral Nervous System Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Spasticity indication 221360009
Muscle Spasm with Pain indication
Alcoholism contraindication 7200002
Hepatic failure contraindication 59927004
Poisoning by acetaminophen contraindication 70273001
Liver function tests abnormal contraindication 166603001
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.22 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
375MG CHLORZOXAZONE NOVITIUM PHARMA A212253 Nov. 27, 2019 RX TABLET ORAL May 25, 2020 COMPETITIVE GENERIC THERAPY
750MG CHLORZOXAZONE NOVITIUM PHARMA A212253 Nov. 27, 2019 RX TABLET ORAL May 25, 2020 COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Calcium-activated potassium channel subunit alpha-1 Ion channel OPENER EC50 4.52 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Intermediate conductance calcium-activated potassium channel protein 4 Ion channel ACTIVATOR EC50 4 IUPHAR
Nitric oxide synthase, inducible Enzyme IC50 4.85 CHEMBL
Nitric oxide synthase, brain Enzyme IC50 4.30 CHEMBL
Nitric oxide synthase, endothelial Enzyme IC50 5.06 CHEMBL
Nitric oxide synthase, brain Enzyme IC50 5.55 DRUG MATRIX
Small conductance calcium-activated potassium channel protein 2 Unclassified ACTIVATOR EC50 4.10 IUPHAR

External reference:

IDSource
D002753 MESH_DESCRIPTOR_UI
4017882 VUID
N0000146235 NUI
C0008296 UMLSCUI
D00771 KEGG_DRUG
44908000 SNOMEDCT_US
400361007 SNOMEDCT_US
4369 MMSL
2410 RXNORM
4433 MMSL
d00962 MMSL
4017882 VANDF
001671 NDDF
2733 PUBCHEM_CID
CHEBI:3655 CHEBI
CHEMBL1371 ChEMBL_ID
DB00356 DRUGBANK_ID
H0DE420U8G UNII
748 INN_ID
CLW PDB_CHEM_ID
2322 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 0591-2520 TABLET 500 mg ORAL ANDA 11 sections
chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 13811-717 TABLET 375 mg ORAL ANDA 11 sections
chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 13811-718 TABLET 750 mg ORAL ANDA 11 sections
CHLORZOXAZONE HUMAN PRESCRIPTION DRUG LABEL 1 16590-478 TABLET 500 mg ORAL ANDA 11 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 21695-569 TABLET 500 mg ORAL ANDA 11 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 33261-021 TABLET 500 mg ORAL ANDA 11 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 42254-076 TABLET 500 mg ORAL ANDA 11 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 42494-425 TABLET 375 ug ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 42494-426 TABLET 500 ug ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 42494-427 TABLET 500 ug ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 42494-428 TABLET 750 ug ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 45865-434 TABLET 500 mg ORAL ANDA 11 sections
chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 46672-117 TABLET 750 mg ORAL ANDA 12 sections
chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 46672-118 TABLET 375 mg ORAL ANDA 12 sections
chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 46672-860 TABLET 250 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 49999-044 TABLET 500 mg ORAL ANDA 10 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 50090-0315 TABLET 500 mg ORAL ANDA 11 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 50090-0316 TABLET 500 mg ORAL ANDA 11 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 53002-5760 TABLET 500 mg ORAL ANDA 11 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 54868-0735 TABLET 500 mg ORAL ANDA 11 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 55045-1594 TABLET 500 mg ORAL ANDA 12 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 55289-633 TABLET 500 mg ORAL ANDA 11 sections
Lorzone HUMAN PRESCRIPTION DRUG LABEL 1 55700-517 TABLET 375 mg ORAL ANDA 11 sections
CHLORZOXAZONE HUMAN PRESCRIPTION DRUG LABEL 1 61919-478 TABLET 500 mg ORAL ANDA 11 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 63187-317 TABLET 500 mg ORAL ANDA 11 sections
Chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 66336-663 TABLET 500 mg OCCLUSIVE DRESSING TECHNIQUE ANDA 11 sections
Lorzone HUMAN PRESCRIPTION DRUG LABEL 1 68025-046 TABLET 375 mg ORAL ANDA 12 sections
Lorzone HUMAN PRESCRIPTION DRUG LABEL 1 68025-047 TABLET 750 mg ORAL ANDA 12 sections
Parafon DSC HUMAN PRESCRIPTION DRUG LABEL 1 68387-375 TABLET 500 mg ORAL ANDA 11 sections
chlorzoxazone HUMAN PRESCRIPTION DRUG LABEL 1 69499-330 TABLET 250 mg ORAL ANDA 12 sections